Tesamorelin vs sermorelin vs ipamorelin: compare how each peptide raises growth hormone, their FDA status, half-lives, side effects, and clinical evidence.
Tesamorelin, sermorelin, and ipamorelin all signal the pituitary gland to release more growth hormone, but they act through different receptors and have very different legal statuses in the United States. Tesamorelin is the only one of the three with FDA approval, sermorelin is a GHRH analog used off-label, and ipamorelin is a selective ghrelin mimetic that is not approved for human use. Choosing among them, if you choose at all, depends on your goal, your health history, and advice from a licensed clinician.
Searches for sermorelin vs tesamorelin vs ipamorelin, or the same three compounds typed in a different order, are usually asking one question: which is most effective, which is safest, and which is legal?
The Short Answer: Same Goal, Different Pathways
- Tesamorelin is a stabilized GHRH analog sold as Egrifta, approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
- Sermorelin is a shorter GHRH analog, once FDA-approved for pediatric growth hormone deficiency and now used off-label.
- Ipamorelin is a five-amino-acid ghrelin receptor agonist studied for relatively selective growth hormone release.
Because their mechanisms differ, these peptides are not simply stronger or weaker versions of one another.
How Each Peptide Works
Tesamorelin
Tesamorelin binds GHRH receptors in the pituitary, prompting endogenous growth hormone release and a rise in IGF-1. It is the most studied of the three in humans, with randomized trials measuring visceral adipose tissue. It is given as a daily subcutaneous injection.
Sermorelin
Sermorelin uses the same receptor but has a much shorter half-life, often reported at 10 to 20 minutes. That short window is why it is frequently compared with longer-acting GHRH analogs in research settings.
Ipamorelin
Ipamorelin stimulates the ghrelin receptor, also called GHS-R1a, instead of the GHRH receptor. Animal data suggests it triggers growth hormone release with limited effects on cortisol, prolactin, and appetite compared with older ghrelin mimetics. Human data is scarce.
Tesamorelin vs Sermorelin vs Ipamorelin: Comparison Table
| Feature | Tesamorelin | Sermorelin | Ipamorelin |
|---|---|---|---|
| Class | GHRH analog | GHRH analog | Ghrelin mimetic |
| Receptor | GHRH-R | GHRH-R | GHS-R1a |
| FDA approval | Approved for HIV lipodystrophy | Not currently approved | Not approved for human use |
| Approximate half-life | 26 to 38 minutes | 10 to 20 minutes | About 2 hours |
| Strongest human data | Visceral fat reduction | Growth hormone and IGF-1 stimulation | Limited |
| Typical route | Subcutaneous injection | Subcutaneous injection | Subcutaneous injection |
FDA Status and Legal Reality in the US
Tesamorelin is a prescription drug approved for a specific diagnosis, which means it must be prescribed by a licensed clinician and dispensed by a pharmacy. It is not a supplement.
Sermorelin and ipamorelin are not FDA-approved for any human use. Regulators have also restricted compounding of several growth hormone-related peptides, including ipamorelin, citing significant safety concerns.
Vials sold as study material online are not a legal workaround. Those products are not verified for identity, purity, or sterility, and injecting them carries real risk.
What the Research Actually Shows
Randomized human trial data is strongest for tesamorelin, where sustained treatment reduced visceral fat in patients with HIV lipodystrophy. Sermorelin has decades of data on growth hormone stimulation but far less on body composition. Ipamorelin's evidence base is mostly animal pharmacology.
No peptide in this group is a proven anti-aging cure, and none is approved for general weight loss.
Many researchers also look into cjc-1295 ipamorelin vs tesamorelin when weighing a two-peptide approach against a single approved compound.
Stacking and Combination Questions
Some protocols stack tesamorelin and ipamorelin to target the GHRH and ghrelin pathways at the same time. Others use a combination discussed online as the cjc 1295 ipamorelin tesamorelin stack.
Stacking can push IGF-1 higher than a single agent, which raises the theoretical risk of fluid retention, joint pain, and carpal tunnel symptoms. There is no large clinical trial supporting these combinations.
ipamorelin vs mk-677 is another common comparison, because MK-677 hits the same ghrelin receptor but is taken orally instead of injected. sermorelin vs aod 9604 is a different question entirely, since AOD 9604 is a fat-metabolism fragment rather than a growth hormone secretagogue.
Side Effects and Safety
Reported side effects of GHRH analogs include injection site reactions, headache, flushing, joint pain, and swelling. Because all three peptides raise IGF-1, long-term use raises questions about tissue growth effects that researchers are still studying.
Tesamorelin labeling calls for IGF-1 monitoring and lists pregnancy as a contraindication. Anyone with a history of cancer, pituitary disease, or uncontrolled diabetes should not use these compounds without specialist oversight.
This article is educational and is not medical advice. Speak with a qualified healthcare professional before starting, stopping, or combining any peptide.
How to Decide
- Define your goal, whether that is visceral fat, body composition, or basic research.
- Weigh the evidence: tesamorelin has the most human data and ipamorelin the least.
- Check legality, since only tesamorelin is FDA-approved and available by prescription.
- Review your health history for contraindications.
- Get baseline labs and clinical supervision if you and your clinician decide to proceed.
Frequently Asked Questions
Which is stronger, tesamorelin or ipamorelin?
They cannot be compared directly because tesamorelin acts on the GHRH receptor and ipamorelin acts on the ghrelin receptor. Tesamorelin has the strongest human trial evidence, mainly for reducing visceral fat, while ipamorelin's reputation for producing a clean growth hormone pulse comes mostly from animal studies.
Is sermorelin or tesamorelin better for fat loss?
Tesamorelin is the only one of the two approved for a fat-related indication, so it has by far the most supporting clinical trial data. Sermorelin has decades of research on growth hormone stimulation but very little on body composition. Neither peptide is approved for general weight loss.
Are tesamorelin, sermorelin, and ipamorelin FDA-approved?
Tesamorelin is FDA-approved as a prescription drug for excess abdominal fat in adults with HIV-associated lipodystrophy. Sermorelin and ipamorelin are not approved for human use, and the FDA has restricted compounding of several growth hormone-related peptides over safety concerns. Buying research-labeled vials online is neither a legal nor a safe substitute for a prescription.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.